Wall Street analysts forecast that Avanos Medical Inc (NYSE:AVNS) will announce sales of $167.47 million for the current quarter, according to Zacks. Three analysts have provided estimates for Avanos Medical’s earnings, with estimates ranging from $166.70 million to $168.70 million. Avanos Medical posted sales of $401.40 million in the same quarter last year, which would indicate a negative year over year growth rate of 58.3%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, November 7th.
On average, analysts expect that Avanos Medical will report full-year sales of $670.05 million for the current fiscal year, with estimates ranging from $665.90 million to $673.38 million. For the next financial year, analysts expect that the firm will post sales of $731.88 million per share, with estimates ranging from $722.80 million to $738.81 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Avanos Medical.
A number of equities analysts have recently weighed in on the stock. KeyCorp lifted their price target on shares of Avanos Medical from $66.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 8th. Morgan Stanley lifted their price target on shares of Avanos Medical from $58.00 to $60.00 and gave the stock an “underweight” rating in a research report on Wednesday, August 8th. Zacks Investment Research raised shares of Avanos Medical from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a research report on Thursday, August 9th. Finally, Raymond James raised shares of Avanos Medical from a “market perform” rating to an “outperform” rating in a research report on Tuesday, August 21st.
AVNS stock traded down $1.02 during midday trading on Friday, reaching $71.39. The company’s stock had a trading volume of 267,092 shares, compared to its average volume of 316,084. Avanos Medical has a 52 week low of $41.51 and a 52 week high of $72.96. The stock has a market cap of $3.36 billion, a PE ratio of 27.68 and a beta of 1.76. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.18 and a current ratio of 2.48.
An institutional investor recently bought a new position in Avanos Medical stock. Oregon Public Employees Retirement Fund purchased a new position in shares of Avanos Medical Inc (NYSE:AVNS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 18,038 shares of the company’s stock, valued at approximately $1,033,000. Hedge funds and other institutional investors own 84.85% of the company’s stock.
Avanos Medical Company Profile
Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.
Featured Story: Hedge Funds – How They Work For Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.